FDA New Drug and Biologic Approvals -- 2017 Year-in-Review

Mary L Windle, PharmD

January 11, 2018

In This Article

Other Notable Approvals

Endari (L-glutamine)

First drug approval for sickle cell disease in nearly 20 years. Indicated to reduce severe complications of sickle cell disease in adults and children aged 5 years or older.

Nucala (mepolizumab)

First approved therapy specifically for adults with eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome.

Repatha (evolocumab)

First PCSK9 inhibitor approved to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Mary L Windle. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review - Medscape - Jan 11, 2018.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.